Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (131-140 of 200) with videos related to

Pageof 20
Sort By:
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|September 7, 2016
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' replyMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The European Respiratory Journal|December 7, 2013
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisRoland M du Bois, Carlo Albera, Williamson Z Bradford, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 30, 2008
CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosisBenjamin Wilde, Sebastian Dolff, Xin Cai, et al.
The European Respiratory Journal|October 3, 2020
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosisToby M Maher, Ulrich Costabel, Marilyn K Glassberg, et al.
Respiratory Medicine|June 2, 2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairmentSteven D Nathan, Ulrich Costabel, Carlo Albera, et al.
International Immunopharmacology|May 17, 2026
Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosisYueyin Han, Mengyuan Liu, Wenxiu Xu, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2014
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trialsTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
American Journal of Respiratory and Critical Care Medicine|August 2, 2008
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trialGanesh Raghu, Kevin K Brown, Ulrich Costabel, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosisMatthew J Loza, Carrie Brodmerkel, Roland M Du Bois, et al.
Pageof 20

Showing results (131-140 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. Respiratory Medicine|April 7, 2016
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysisMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The Lancet. Respiratory Medicine|September 7, 2016
Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution - Authors' replyMichael Kreuter, Wim Wuyts, Elisabetta Renzoni, et al.
The European Respiratory Journal|December 7, 2013
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisRoland M du Bois, Carlo Albera, Williamson Z Bradford, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 30, 2008
CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosisBenjamin Wilde, Sebastian Dolff, Xin Cai, et al.
The European Respiratory Journal|October 3, 2020
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosisToby M Maher, Ulrich Costabel, Marilyn K Glassberg, et al.
Respiratory Medicine|June 2, 2019
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairmentSteven D Nathan, Ulrich Costabel, Carlo Albera, et al.
International Immunopharmacology|May 17, 2026
Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosisYueyin Han, Mengyuan Liu, Wenxiu Xu, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2014
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trialsTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
American Journal of Respiratory and Critical Care Medicine|August 2, 2008
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trialGanesh Raghu, Kevin K Brown, Ulrich Costabel, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2011
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosisMatthew J Loza, Carrie Brodmerkel, Roland M Du Bois, et al.
Pageof 20